Australian clinical-stage company Immutep has announced positive data from the INSIGHT-003 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer. …
Australian company says 'Efti' INSIGHT-003 lung cancer trial reveals positive survival data
November 14, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Pharmacy Guild welcomes new qualification for the profession
November 21, 2024 - - Latest News -
Amgen welcomes expanded listing of biologic osteoporosis therapy
November 21, 2024 - - Latest News -
Few are better qualified to make a difference, as long as they are allowed to
November 21, 2024 - - Latest News -
Will the implementation group members take a principled stand against secrecy on behalf of the broader community?
November 20, 2024 - - Latest News -
Telix announces agreement to add FAP-targeting candidates to theranostic pipeline
November 20, 2024 - - Latest News -
GBMA says Australia can benefit from a biosimilar medicines funding windfall
November 20, 2024 - - Latest News -
Ramsay Health Care and Bupa join forces to develop our next generation of nurses
November 19, 2024 - - Other Health